LeoVegas completes the acquisition of the gaming operator Royal Panda
On 24 October LeoVegas published a press release regarding the acquisition of the gaming operator Royal Panda. The acquisition was subject to approval by the Maltese authorities and LeoVegas hereby announces that all conditions have now been met and that the acquisition and access of the shares is completed as of today.
The acquisition of Royal Panda strengthens LeoVegas' expansion in regulated gaming markets, especially in the UK, and adds a strong and exciting brand to the LeoVegas Group. The acquisition is being made for a purchase price of EUR 60 m with a possible earn-out payment of an additional EUR 60 m. The total purchase consideration can thus amount to a maximum of EUR 120 m. The calculation of the earn-out payment and additional purchase price will commence from 1 December 2017.
For more information regarding the acquisition please refer to the press release published on 24 October 2017 and to LeoVegas interim report for the third quarter of 2017 published the 25th of October 2017. The press release and the quarterly report can be found on www.leovegasgroup.com.
For further information, please contact:
Gustaf Hagman, Group CEO and co-founder: +46 70-880 55 22, firstname.lastname@example.org
Viktor Fritzén, Group CFO: +46 73-612 26 67, email@example.com
Philip Doftvik, Head of Corporate Finance and Investor Relations: +46 73 512 07 20, firstname.lastname@example.org
Visitors address: Sveavägen 59, Stockholm
Corporate identity number: 556830-4033
About the LeoVegas mobile gaming group
LeoVegas' vision is to create the ultimate mobile gaming experience and be number one in mobile casino. The business is distinguished by award-winning innovation and strong growth. LeoVegas' technical development is conducted in Sweden, while operations are based in Malta. The Swedish parent company LeoVegas AB (publ) invests in companies that offer gaming via mobile devices and desktop computers along with companies that develop related technologies. LeoVegas has attracted major international acclaim and has won numerous awards, including "Operator of the year", "Mobile Marketing Campaign of the year", and "Innovation in Mobile and Tablet of the Year" at the international EGR Awards. LeoVegas bases its development on "Mobile First" and is at the forefront of using state-of-the-art technology in the mobile gaming market. With a foundation in a great gaming experience, long-term customer relationships and establishment of a strong brand, the company has attracted a steadily growing customer base through innovative, effective and data-driven marketing. Since its start, the mobile gaming company LeoVegas has shown strong quarter-on-quarter growth. LeoVegas' shares are listed on Nasdaq First North Premier. Avanza Bank AB is the company's Certified Adviser. For more about LeoVegas, visit www.leovegasgroup.com or www.leovegas.com .
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LeoVegas AB via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller22.11.2017 11:39 | Pressmeddelande
The sale will be the most significant philanthropic auction ever presented LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, announces today its worldwide sponsorship of the exhibition and tour of The Collection of Peggy and David Rockefeller, the most significant auction entirely dedicated to raising funds for philanthropic causes. The sale, consisting of numerous categories, will be conducted by Christie's, the world's leading art business, and will include a highlights exhibition tour in Hong Kong, London, Los Angeles and New York. Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c78fdce7-7651-42a8-a621-14088da2cc86 http://www.globenewswire.com/NewsRoom/AttachmentNg/33af2489-a9a8-4bbe-b5f7-78e4c1f29ca2 http://www.globenewswire.com/NewsRoom/AttachmentNg/a16c2
Nasdaq to Deliver Blockchain e-Voting Solution to Strate22.11.2017 10:00 | Pressmeddelande
South Africa's central securities depository (CSD) will leverage the solution to improve voting efficiencies and increase shareholder participation in South Africa STOCKHOLM, Sweden and JOHANNESBURG, South Africa, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) and Strate (Pty) Ltd, the South African CSD, announced today an agreement for Nasdaq to deliver a new blockchain solution that would bring electronic voting to the South African capital markets. The solution will allow Strate, in conjunction with key stakeholders in the market, to provide general meeting services and give shareholders an easy, user-friendly and secure tool for voting remotely. The solution is based on the successful proof of concept (PoC) developed for Nasdaq's Estonia market. In addition, Strate will contribute to the ongoing market development of e-Voting technology. "We are very excited about our initiative with Nasdaq and what it means for the South African financial markets," said Tan
Immunicum AB: Invitation to Investor Events22.11.2017 08:00 | Pressmeddelande
Press release November 22, 2017 Invitation to Investor Events Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. Aktiespararna Stora Aktiedagen in Gothenburg Date: Monday, November 27, 2017 Presentation Time: 10:10-10:40 CET Location: Svenska Mässan, Mässans Gata 8, Gothenburg Please register to attend at https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg. Immunicum Investor Event in Stockholm Date: Thursday, November 30, 2017 Presentation Time: 18:00-19:00 CET Location: United Spaces, Waterfront Building, Floor 2, Klarabergsviadukt
Immunicum AB: Inbjudan till investerarmöten22.11.2017 08:00 | Pressmeddelande
Pressmeddelande 22 november 2017 Inbjudan till investerarmöten Immunicum AB (publ), First North Premier: (IMMU.ST), ett bioteknikbolag som utvecklar nya immunaktiverande cancerbehandlingar för ett antal solida tumörer, meddelar dag att VD Carlos de Sousa kommer att presentera bolaget samt bakgrunden till bolagets föreslagna nyemission vid två kommande investerarmöten. Stora Aktiedagen i Göteborg, Aktiespararna Datum: Måndagen den 27 november, 2017 Plats: Svenska Mässan, Mässans gata 8, Göteborg Tid: Kl 10.10 - 10.40 i sal 4 Vänligen anmäl deltagande via https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg. Immunicums investerarmöte i Stockholm Tid: Kl. 18.00 torsdagen 30 november 2017 Plats: United Spaces, Waterfront, Klarabergsviadukten 63 plan 2, Stockholm Det bjuds på lättare förtäring och dryck efter presentationen.
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00 | Pressmeddelande
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856 Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum